3D-011 is under clinical development by 3D Medicines and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 3D-011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
3D-011 overview
3D-011 is under development for the treatment of advanced or metastatic malignant solid tumors including advanced or metastatic hepatocellular carcinoma, advanced renal cell carcinoma and metastatic castration-resistant prostate cancer. It acts by targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor are receptor tyrosine kinases (PDGFR). It is administered through intravenous drip route.
3D Medicines overview
3D Medicines is a precision medicine company that provides cancer precision medical treatment. The company pipe line products include advanced cancer therapy products, multiple indications therapy products, cancer pain and osteoarthritis therapy products, metastatic solid tumors therapy products, advanced malignant solid tumors therapy products. It offers cancer diagnosis and treatment through the integration of biological characteristics, clinical diagnosis and treatment, and drug research and development data mining applications. The company also offers precision cancer prevention, precision cancer diagnosis, and precision drug development. 3D Medicines provide services for different people, which cover tumor tissue and blood samples. It operates in China, Japan and the US. 3D Medicines is headquartered in Qingdao, Shandong, China.
For a complete picture of 3D-011’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - 3D-011 in Solid Tumor
Premium Insights
The gold standard of business intelligence.
